Patents Assigned to Pfizer
  • GLP-1 Agonists and Uses Thereof
    Publication number: 20180170908
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 21, 2018
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • THERAPEUTIC ANTIBODIES AND THEIR USES
    Publication number: 20180171018
    Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
    Type: Application
    Filed: January 23, 2018
    Publication date: June 21, 2018
    Applicant: PFIZER INC.
    Inventors: Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
  • PD-L1 Antagonist Combination Treatments
    Publication number: 20180169232
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 21, 2018
    Applicants: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Glen Ian ANDREWS, Shihao CHEN, Alessandra DI PIETRO, David FONTANA, Zelanna GOLDBERG, Chia-Yang LIN, Hua LONG, Marcella MARTIGNONI, Dimitry Serge Antoine NUYTEN, Aron David THALL, Adrian WOOLFSON
  • N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
    Publication number: 20180162858
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: January 30, 2018
    Publication date: June 14, 2018
    Applicant: PFIZER INC.
    Inventors: Mary Didiuk, Robert Lee Dow, David Andrew Griffith
  • BISPECIFIC HETERODIMERIC DIABODIES AND USES THEREOF
    Publication number: 20180155452
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 7, 2018
    Applicant: Pfizer Inc.
    Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
  • PCSK9 vaccine
    Patent number: 9987341
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: June 5, 2018
    Assignee: Pfizer Vaccines LLC
    Inventors: Brian Robert Champion, Jr., Leonard Gabriel Contillo, Jr., Michael Dale Eisenbraun, James Downey Fraser, Julie Jia Li Hawkins, James Richard Merson, Brian Gregory Pierce, Xiayang Qiu, Jakir Hussain Ullah, David Michael Wyatt
  • NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME
    Publication number: 20180148420
    Abstract: Compounds, pharmaceutically acceptable salts thereof are disclosed wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: May 16, 2016
    Publication date: May 31, 2018
    Applicant: Pfizer Inc.
    Inventors: Agustin Casimiro-Garcia, Jeffrey Scott Condon, Andrew Christopher Flick, Ariamala Gopalsamy, Steven J. Kirincich, John Paul Mathias, Joseph Walter Strobach, Jason Shaoyun Xiang, Li Huang Xing, Xiaolun Wang
  • HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS
    Publication number: 20180148432
    Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (?-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.
    Type: Application
    Filed: November 22, 2017
    Publication date: May 31, 2018
    Applicant: Pfizer Inc.
    Inventors: Natasha Mariam Kablaoui, Michael Eric Green, Justin Ian Montgomery, Michael Aaron Brodney, Patrick Robert Verhoest, Gregory Wayne Kauffman, Danica Antonia Rankic, Scot Richard Mente, Bruce Nelsen Rogers, Kapildev Kashmirilal Arora, Matthew Francis Dunn
  • Cycloalkyl-Linked Diheterocycle Derivatives
    Publication number: 20180148441
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Application
    Filed: November 29, 2017
    Publication date: May 31, 2018
    Applicant: PFIZER INC.
    Inventors: Aaron Craig BURNS, Michael Raymond COLLINS, Samantha Elizabeth GREASLEY, Robert Louis Hoffman, Peter Qinhua HUANG, Robert Steven Kania, Pei-Pei KUNG, Maria Angelica LINTON, Lakshmi Sourirajan NARASIMHAN, Paul Francis RICHARDSON, Daniel Tyler RICHTER, Graham SMITH
  • STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES
    Publication number: 20180140714
    Abstract: The present invention provides stability-modulated antibody-drug conjugates, stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, therapeutic methods using stability-modulated antibody-drug conjugates, and methods of making stability modulating linkers and stability-modulated antibody-drug conjugates.
    Type: Application
    Filed: August 14, 2015
    Publication date: May 24, 2018
    Applicants: PFIZER INC., RINAT NEUROSCIENCE CORP.
    Inventors: Russell George DUSHIN, Pavel STROP, Magdalena Grazyna DORYWALSKA, Ludivine MOINE
  • Dual-ended lip balm container
    Patent number: 9974377
    Abstract: A three to six sided lip balm applicator of the present invention comprises a cap, a liner, and a base, having engagement assemblies for engaging the cap to the liner, the liner to the base, and a base from one lip balm applicator to an equivalent base from another lip balm applicator to form a lip balm container. The base comprises a partition with stabilizers which emerge from the partition and extend radially toward and overhang an aperture in the partition. The lip balm applicator may contain a domed lip balm, filled directly into the lip balm applicator or components thereof as a mold for manufacturing the domed lip balm, filled to a fill level approaching the partition top but not touching the partition top.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: May 22, 2018
    Assignee: Pfizer Inc.
    Inventors: Matthew Clifton Keller, David Dombrowski, David Charles Fuhrmeister, William H. Valls, Zachariah S. Simmering, Jonathon Keith Markey
  • INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES
    Publication number: 20180134656
    Abstract: The present invention relates to intermediates of Formula I and to methods of synthesizing and purifying calicheamicin derivatives.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 17, 2018
    Applicant: PFIZER INC.
    Inventors: Robert Wayne Dugger, Leo Joseph Letendre, Vimalkumar Babubhai Patel, Amarnauth Shastrie Prashad, Chunchun Zhang
  • Therapeutic antibodies and their uses
    Patent number: 9969809
    Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: May 15, 2018
    Assignee: PFIZER INC.
    Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
  • THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20180125854
    Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles.
    Type: Application
    Filed: January 3, 2018
    Publication date: May 10, 2018
    Applicant: PFIZER INC.
    Inventors: Shubha Bagrodia, Jennifer Lafontaine, Zach Lovatt, Eyoung Shin, Young Ho Song, Greg Troiano, Hong Wang
  • Bicyclic-Fused Heteroaryl or Aryl Compounds
    Publication number: 20180127432
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: January 5, 2018
    Publication date: May 10, 2018
    Applicant: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Human monoclonal antibodies to CTLA-4
    Patent number: 9963508
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: May 8, 2018
    Assignees: AMGEN FREMONT INC., PFIZER INC.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • RSV F protein mutants
    Patent number: 9950058
    Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: April 24, 2018
    Assignee: Pfizer Inc.
    Inventors: Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
  • Glycoconjugation processes and compositions
    Patent number: 9950054
    Abstract: The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: April 24, 2018
    Assignee: Pfizer Inc.
    Inventors: Jianxin Gu, Jin-hwan Kim, Avvari Krishna Prasad, Yu-ying Yang
  • Twist-off bottle cap with finger notches
    Patent number: D815943
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: April 24, 2018
    Assignee: Pfizer Inc.
    Inventor: Edward Candelaria
  • Twist-off bottle cap with finger notches
    Patent number: D816494
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 1, 2018
    Assignee: Pfizer Inc.
    Inventor: Edward Candelaria